CereVasc Revenue and Competitors
Estimated Revenue & Valuation
- CereVasc's estimated annual revenue is currently $2.3M per year.
- CereVasc's estimated revenue per employee is $125,500
- CereVasc's total funding is $44M.
Employee Data
- CereVasc has 18 Employees.
- CereVasc grew their employee count by 6% last year.
CereVasc's People
| Name | Title | Email/Phone |
|---|---|---|
1 | SVP & Chief Financial Officer | Reveal Email/Phone |
2 | Director, Marketing | Reveal Email/Phone |
CereVasc Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $9.8M | 39 | 3% | N/A | N/A |
#2 | $8.5M | 34 | 3% | N/A | N/A |
#3 | $3M | 12 | -29% | N/A | N/A |
#4 | $5630M | 7477 | -11% | $450M | N/A |
#5 | $4.5M | 18 | 6% | N/A | N/A |
#6 | $7.2M | 57 | 27% | $29.6M | N/A |
#7 | $14.3M | 57 | -12% | N/A | N/A |
#8 | $2.3M | 18 | 6% | $44M | N/A |
#9 | $40.7M | 162 | -1% | N/A | N/A |
#10 | $45.7M | 182 | -5% | N/A | N/A |
What Is CereVasc?
CereVasc, Inc. is developing the eShuntâ„¢ System for the treatment of patients with communicating hydrocephalus, one of the most common neurological conditions affecting both children and adults.
keywords:N/A
$44M
Total Funding
18
Number of Employees
$2.3M
Revenue (est)
6%
Employee Growth %
N/A
Valuation
N/A
Accelerator
CereVasc News
Clinical trial underway in Argentina to study minimally invasive treatment for NPH. BOSTON, April 25, 2022 /PRNewswire/ -- CereVasc, Inc.,...
CereVasc, Inc., a Boston, MA-based company focused on improving the treatment of patients with hydrocephalus, closed an expanded Series A financing that raised a total of $43.9m. The round was led by the Perceptive Xontogeny Venture (PXV) Fund and ATON Partners, LLC. Led by Dan Levangie, Chair ...
BOSTON--(BUSINESS WIRE)--CereVasc, Inc., a company focused on improving the treatment of patients with hydrocephalus, announced today the closing of an expanded Series A financing that raised a total of $43.9 million led by the Perceptive Xontogeny Venture (PXV) Fund and ATON Partners, LLC. The ...
– Proceeds to fund clinical trials of the eShunt™ System for treatment of hydrocephalus – – Series A financing led by the Perceptive Xontogeny Venture Fund – BOSTON–(BUSINESS WIRE)–June 9, 2020– CereVasc, Inc., a company focused on improving the treatment of patients with hydrocephalus, annou ...
Other Companies in Auburndale
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $5.6M | 28 | 4% | N/A |
#2 | $3.6M | 37 | 6% | N/A |
#3 | N/A | 45 | 15% | N/A |
#4 | $35M | 53 | -10% | N/A |
#5 | $5.7M | 53 | 6% | N/A |